14 May 2021
The 2020 ESC Guidelines of acute coronary syndrome highlights new major changes and recommendations in the diagnosis, risk stratification, and treatment of patients presenting without ST-segment elevation.
Two of the major changes from the guidelines include the use of CCTA as an alternative non-invasive means to exclude ACS when there is a low-to-intermediate likelihood of CAD and when cardiac markers and/or ECG are normal or inconclusive. The second one is the consideration of adding a second antithrombotic agent in patients at high risk of ischaemic events and without increased risk of major or life-threatening bleeding.
Some new key recommendations regarding diagnostic biomarkers, P2Y12 receptor inhibitor, antiplatelet treatment, and early invasive strategy can also be found in the guidelines.
Read the rest of the article at https://www.instagram.com/p/CN95AB_HBeV/
Want to know more about acute coronary syndrome?
Join us at the online Acute Coronary Syndrome Symposium on August 14th 2021 and further enhance your knowledge.